ArticlePDF Available

Diet Drink Consumption and the Risk of Cardiovascular Events: A Report from the Women’s Health Initiative

Authors:

Abstract and Figures

Background: Data are limited regarding the influence of diet drink consumption on cardiovascular disease (CVD) outcomes. Objective: We aimed to evaluate the relationship between diet drink intake and cardiovascular events. Design: We conducted a retrospective cohort study, utilizing data from the national, multicenter Women's Health Initiative Observational Study (WHI OS), recruiting subjects from 1993 to 1998. Patients: Post-menopausal women with available diet drink intake data, without pre-existing CVD and who survived ≥ 60 days were included in the study. Main meaures: A composite of incident coronary heart disease, heart failure, myocardial infarction, coronary revascularization procedure, ischemic stroke, peripheral arterial disease and CVD death was used as the primary outcome. CVD death and all-cause mortality were secondary outcomes. Adjusted Cox proportional hazards models were used to compare primary and secondary outcomes across diet drink intake strata. Key results: In all, 59,614 women, mean age 62.8 years, were included for analysis. In unadjusted analysis over a follow-up of 8.7 ± 2.7 years, the primary outcome occurred in 8.5 % of the women consuming ≥ 2 diet drinks/day, compared to 6.9 %, 6.8 % and 7.2 % in the 5-7/week, 1-4/week and 0-3/month groups, respectively. After controlling for other CVD risk factors, women who consumed ≥ 2 drinks/day had a higher adjusted risk of CVD events (HR 1.3, 95 % CI 1.1-1.5), CVD mortality (HR 1.5, 95 % CI 1.03-2.3) and overall mortality (HR 1.3, 95 % CI 1.04-1.5) compared to the reference group (0-3 drinks/month). Conclusions: This analysis demonstrates an association between high diet drink intake and CVD outcomes and mortality in post-menopausal women in the WHI OS.
Content may be subject to copyright.
Diet Drink Consumption and the Risk of Cardiovascular Events:
A Report from the Womens Health Initiative
Ankur Vyas, MD
1
, Linda Rubenstein, PhD
2
, Jennifer Robinson, MD, MPH
1,2
,
Rebecca A. Seguin, PhD, CSCS
3
, Mara Z. Vitolins, DrPH, MPH, RD
4
,
Rasa Kazlauskaite, MD, MSc, FACE
5,6
, James M. Shikany, DrPH
7
, Karen C. Johnson, MD, MPH
8
,
Linda Snetselaar, RD, PhD
2
, and Robert Wallace, MD, MSc
2,9
1
Division of Cardiovascular Medicine, University of Iowa Hospitals & Clinics, Iowa City, IA, USA;
2
Department of Epidemiology, College of Public Health,
University of Iowa, Iowa City, IA, USA;
3
Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA;
4
Department of Epidemiology & Prevention, Wake
Forest School of Medicine, Winston-Salem, NC, USA;
5
Department of Preventive Medicine, Rush University, Chicago, IL, USA;
6
Department of Internal
Medicine, Rush University, Chicago, IL, USA;
7
Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, USA;
8
Department of
Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, USA;
9
Department of Internal Medicine, University of Iowa Hospitals and
Clinics, Iowa City, IA, USA.
BACKGROUND: Data are limited regarding the influence
of diet drink consumption on cardiovascular disease
(CVD) outcomes.
OBJECTIVE: We aimed to evaluate the relationship be-
tween diet drink intake and cardiovascular events.
DESIGN: We conducted a retrospective cohort study, uti-
lizing data from the national, multicenter Womens Health
Initiative Observational Study (WHI OS), recruiting sub-
jects from 1993 to 1998.
PATIEN T S: Post-menopausal women with available diet
drink intake data, without pre-existing CVD and who
survived 60 days were included in the study.
MAIN MEAURES: A composite of incident coronary heart
disease, heart failure, myocardial infarction, coronary re-
vascularization procedure, ischemic stroke, peripheral
arterial disease and CVD death was used as the primary
outcome. CVD death and all-cause mortality were sec-
ondary outcomes. Adjusted Cox proportional hazards
models were used to compare primary and secondary
outcomes across diet drink intake strata.
KEY RESULTS: In all, 59,614 women, mean age
62.8 years, were included for analysis. In unadjusted
analysis over a follow-up of 8.7±2.7 years, the primary
outcome occurred in 8.5 % of the women consuming 2
diet drinks/day, compared to 6.9 %, 6.8 % and 7.2 % in
the 57/week, 14/week and 03/month groups, respec-
tively. After controlling for other CVD risk factors, women
who consumed 2 drinks/day had a higher adjusted risk
of CVD events (HR 1.3, 95 % CI 1.11.5), CVD mortality
(HR 1.5, 95 % CI 1.032.3) and overall mortality (HR 1.3,
95 % CI 1.041.5) compared to the reference group (03
drinks/month).
CONCLUSIONS: This analysis demonstrates an associa-
tion between high diet drink intake and CVD outcomes
and mortality in post-menopausal women in the WHI OS.
KEY WORDS: diet; cardiovascular diseases; lifestyle; diet drinks; artificial
sweeteners.
J Gen Intern Med
DOI: 10.1007/s11606-014-3098-0
© Society of General Internal Medicine 2014
INTRODUCTION
Observational studies have demonstrated an association be-
tween sugar-sweetened beverages and obesity, metabolic syn-
drome, and cardiovascular disease (CVD) outcomes; this as-
sociation is attributed to increased energy and sugar load.
15
Diet drinks are often consumed as a low-calorie alternative to
sugar-sweetened drinks, and one out of every five Americans
drinks diet soda every day.
6
Several population-based studies
have demonstrated a positive association between diet drinks
and the metabolic syndrome, which in turn is associated with
increased risk for CVD.
2,79
However, data are limited as to
whether there is an increased CVD risk associated with diet
drink consumption. Given the large population directly affect-
ed by such an association, this study was performed to eval-
uate the effect of diet drink consumption on CVD outcomes in
the Womens Health Initiative Observational Study (WHI OS)
cohort.
METHODS
The WHI is a multicenter national study that involved 40
centers across 24 states and the District of Columbia and
included 161,808 postmenopausal women.
10,11
It consisted
of three overlapping Clinical Trials (CT) including 68,133
women, as well as an Observational Study (OS) enrolling
93,676 subjects. Recruitment to the WHI took place from
1993 to 1998, and enrolled postmenopausal women between
50 and 79 years of age.
11
The OS cohort was derived from the
women who were screened for the clinical trials but were
ineligible or unwilling to be randomized, as well as from those
Electronic supplementary material The online version of this article
(doi:10.1007/s11606-014-3098-0) contains supplementary material,
which is available to authorized users.
Received April 21, 2014
Revised August 11, 2014
Accepted October 27, 2014
who responded to a direct invitation to be screened for the
OS.
12
Exclusion criteria (for both the CT and the OS) were the
presence of any medical condition with a predicted survival of
< 3 years, concerns about adherence, and active participation
in other randomized trials. An effort was made to enroll
women of racial and ethnic minority groups, with a target of
20 % of overall enrollment.
13
No significant sampling issues
were noted with regards to participant enrollment. All partic-
ipants provided written informed consent, and the study pro-
tocol was approved by institutional review boards of all par-
ticipating centers.
The OS cohort was used for analysis for this study. After
baseline evaluation at a clinic visit, updates regarding medical
histories and selected exposure data were obtained annually by
mailed questionnaire. All participants were also invited to a
clinic follow-up visit at 3 years after enrollment.
13
Dietary
information was collected using food frequency question-
naires obtained at baseline and follow-up clinic visits.
14
The
questionnaire at follow-up year 3 also included information
regarding diet drink consumption over the previous 3 months.
Diet drink intake was categorized into nine groups on the
questionnaire, ranging from none or less than one per month
to more than six drinks per day, with each drink defined as the
equivalent of a 12-oz can of beverage. Follow-up ended in
2005, and ranged from six to ten years, depending on year of
enrollment.
Inclusion and Exclusion Criteria
All women in the OS for whom diet drink intake data was
available were included for analysis in this study. Exclusion
criteria were (1) presence of any of the following pre-existing
diagnoses: coronary heart disease (CHD), heart failure (HF),
myocardial infarction (MI), coronary revascularization proce-
dure, ischemic stroke, peripheral arterial disease (PAD) as well
as other related cardiovascular and thromboembolic events
(angina, carotid artery disease, hemorrhagic stroke, transient
ischemic attack, pulmonary embolism and deep vein throm-
bosis); or (2) a survival of less than 60 days after collection of
diet drink consumption data.
Outcomes
A composite of incident CHD, HF, MI, coronary revascular-
ization procedure, ischemic stroke, PAD and CVD death was
used as the primary outcome, with time to first occurrence of
any of these events being the relevant endpoint. Secondary
outcomes were rates of CVD death, as well as death from any
cause. Outcomes in the OS were identified through self-report
at annual contacts, and specific details were obtained as need-
ed using standardized questionnaires and request of medical
records.
15
Data linkage with the National Death Index was
performed to assure completeness of survival data, and causes
of death were actively investigated. Adjudication of outcomes
was performed by physicians at the Clinical Centers, the
Clinical Coordinating Center, and the National Institutes of
Health, using a staged approach. All primary and safety end-
points, as well as a sample of locally adjudicated secondary
endpoints, were reviewed centrally. The adjudicating physi-
cians were blinded to any participant information that could
potentially result in bias.
Statistical Analysis
Risk factors and demographic characteristics included base-
line self-reported age, race, education, income, body mass
index (BMI), smoking, alcohol intake, hormone therapy
(HT) use, physical activity, energy intake, salt intake, history
of diabetes,
16
hypertension, or high cholesterol, as well as
sugar-sweetened beverage intake. Age was assessed in years
as both continuous and categorical (4959, 6064, 6569,
70), physical activity was measured as total energy expended,
and energy intake was measured as calibrated total calories.
17
Unadjusted relationships between continuous baseline var-
iables were assessed using t-tests comparing least square
means from general linear models, and between categorical
variables using the Pearson chi-square test. Occurrence of a
CVD event, CVD death and all-cause mortality were mea-
sured in years from the date of Visit 3 until the first CVD
event, death or until the participant was last known to be alive.
Unadjusted differences in incidence of primary and secondary
outcomes across diet drink consumption strata were assessed
using the Pearson chi-square test. Cox proportional hazards
models were used to assess the relationship of diet soda intake
with occurrence of the first CVD event or time to death,
adjusting for CVD risk factors.
18
Hazard ratios (HR) and
95 % confidence intervals (CI) were calculated to measure
the magnitude of the associations. Four different models were
constructed. Model I was unadjusted; Model II was adjusted
for age, race, education and income; Model III was adjusted
for the variables in Model II plus smoking status, BMI, and a
history of diabetes, hypertension and hyperlipidemia; and
Model IV was adjusted for the variables in Model III plus
alcohol intake, log calibrated energy intake, physical activity,
sugar-sweetened beverage intake, salt intake, and HT. Subjects
with missing variables were excluded from analysis. All var-
iables were assessed for the proportional hazards assumption
before inclusion in the model. Adjusted cardiac event models
were stratified on hypertension and high cholesterol, and
adjusted mortality models were stratified on hypertension
and the history of diabetes, because these variables did not
meet the proportional hazards assumption.
Additional sensitivity and exploratory analyses were also
performed. In order to decrease the risk of reverse causality,
women with a history of diabetes, hypertension, and high
cholesterol were excluded and the adjusted risk (Model IV
above) for the primary outcome was calculated in the residual
healthier population. The impact of missing salt intake and
calibrated energy intake data was evaluated by constructing
fully adjusted models for the primary outcome after excluding
these variables. The effect of BMI on the relationship between
relationship of diet drink intake and outcomes was further
investigated by using interaction terms for BMI and diet drink
Vyas et al.: Diet Drinks and Cardiovascular Events JGIM
categories in the fully adjusted models. The role of diet quality
was assessed by including Healthy Eating Index-2005 (HEI-
2005) scores in the model (with salt and energy intake exclud-
ed to prevent double counting). HEI-2005 has previously been
used in the WHI and other population based cohorts, and has
been demonstrated to be associated with both cardiometabolic
risk factors and cardiovascular outcomes and mortality.
1923
Finally, as the definition of HF in the WHI was sub-optimal, a
revised primary outcome that excluded HF was constructed,
and adjusted hazard ratios were calculated for the revised
primary outcome as well as HF alone.
This manuscript was prepared in accordance with the
Strengthening the Reporting of Observational Studies in Epi-
demiology (STROBE) Statement.
24
All statistical significance
was based on two-tailed tests and p values 0.050. Statistical
analyses were performed using SAS 9.3 [SAS System for
Windows, version 9.3. Cary, NC: SAS Institute. 20022010].
RESULTS
Of 93,676 women who were part of the WHI OS, 59,614 met
criteria for this study and were included for analysis (Fig. 1).
Among non-deceased women who met other inclusion
criteria, 9,946 were excluded due to lack of diet drink data
secondary to either absent or partial year 3 follow-up. Those
who were excluded had a higher proportion of women older
than 70 years of age as well as women of African American or
Hispanic race, and had lower income and educational status,
compared to women who were included in the analysis.
Almost two-thirds of those included (38,337 women,
64.3 %) fell into the lowest consumption category (03 drinks
per month), and there were 11,590 (19.4 %), 6,702 (11.2 %)
and 2,985 (5.0 %) women who consumed 14 drinks per
week, 57 drinks per week, and two or more drinks per day,
respectively (Table 1). Categorization of diet drink intake was
constructed in accordance with previous studies and in order to
satisfy proportional hazard assumptions.
1,2,25
The mean fol-
low up was 8.7 (SD±2.7) years. The average age of the
included cohort was 62.8 (SD±7.2) years, and a majority of
women (85.7 %) were white.
Baseline variables differed significantly between the four
groups (Table 1). Women who consumed 2 diet drinks/day
were younger than the other groups, with a mean age of
59.5 years, compared to 63.5 years in the 03 drinks per month
group. There was increased prevalence of diabetes and hyper-
tension in the women who consumed the most diet drinks, and
they had a higher BMI, a greater proportion of smokers and
higher calibrated energy intake. When non-diet drink con-
sumption was assessed across the different diet drink intake
strata, no significant difference was found.
Outcomes
The composite primary outcome occurred in 8.5 % of the
women who consumed 2 diet drinks/day, compared to 6.9,
6.8 and 7.2 % of the women in the 57 drinks/week, 14
drinks/week and 03 drinks/month groups, respectively
(Table 2). Unadjusted incidence of the secondary out-
comes did not differ markedly between the 2diet
drinks/day and 03 diet drinks/month groups, with inci-
dence of CVD death and overall mortality being 1.6 and
7.8 %, respectively, in the highest consumption group, and
1.7 and 7.7 % in the lowest (Table 2).
Cox proportional hazard models demonstrated that women
who consumed 2 drinks/day had a higher unadjusted risk of
experiencing CVD events (in the form of the combined end-
point) as compared to those who consumed 03 drinks/month
(the reference group), with the difference being statistically
significant (Model I; N: 59,614; HR 1.2, 95 % CI 1.041.3)
(Table 3). This increased risk among the highest consumption
category persisted when the models were adjusted progres-
sively for baseline demographic variables (Model II; N:
55,073; HR 1.6, 95 % CI 1.41.9), common CVD risk factors
(Model III; N: 53,037; HR 1.3. 95 % CI 1.21.5), and other
possible confounders (Model IV; N: 33,619; HR 1.3, 95 % CI
1.11.5). No significant difference in risk was found between
the other consumption groups and the reference group, with
regards to the primary endpoint. There was progressive de-
crease in sample size with the Cox proportional hazard models
secondary to missing data, with Model IV especially limited
by missing values for energy and salt intake.
Unadjusted analysis (Model I) did not demonstrate a differ-
ence between the 2 drinks/day group and the 03 drinks/
month group with regards to either CVD death (N: 59,447; HR
0.9, 95 % CI 0.71.2) or overall mortality (N: 59,447; HR 1.0,
95 % CI 0.91.1) (Table 3). However, with adjustment for
baseline demographic characteristics, CVD risk factors and
other confounders, there emerged a significant risk of both
CVD death (Model II: N 55,073, HR 1.8, 95 % CI 1.32.4;
Model III: N 53,037, HR 1.4, 95 % CI 1.041.9; Model IV: N
33,619, HR 1.5, 95 % CI 1.032.3) and overall mortality
(Model II: N 55,073, HR 1.5, 95 % CI 1.31.7; Model III: N
53,037, HR 1.4, 95 % CI 1.21.6; Model IV: N 33,619, HR
1.3, 95 % CI 1.041.5) with consumption of 2 diet drinks/
day. Hazard ratios for adjustment covariates for both primary
and secondary outcomes are listed in the online appendix.
Figure 1 Selection of study cohort.
Vyas et al.: Diet Drinks and Cardiovascular EventsJGIM
Sensitivity and Exploratory Analyses
A history of diabetes, hypertension and high cholesterol was
absent in 38,658 women, and these were classified as being
healthier at baseline. The hazard ratios for the primary outcome
for these were similar to those for the primary analysis;
however, the 95 % confidence intervals were wider and did
not reach statistical significance (Table 4). Salt and calibrated
energy intake data were missing in 18,097 (30.4 %) women,
and this was uniformly distributed across the diet drink con-
sumption groups. Excluding salt and calibrated energy intake
from the model did not result in a significant change in the
Table 1. Baseline Characteristics of Women Included in Analysis
Characteristics Diet drink consumption
03/month 14/week 57/week 2/day p value*
N (%) 38,337 (64.3) 11,590 (19.4) 6,702 (11.2) 2,985 (5.0)
Age (Mean ± SD) 63.5±7.2 62.3±6.9 61.2±6.9 59.5±6.5 < 0.0001
Race (%) < 0.0001
American Indian 128 (0.3) 28 (0.2) 30 (0.4) 13 (0.4)
Asian/Pacific Islander 1,401 (3.7) 270 (2.3) 130 (1.9) 36 (1.2)
African American 2,559 (6.7) 720 (6.2) 387 (5.8) 207 (7.0)
Hispanic 1,282 (3.4) 363 (3.1) 207 (3.1) 98 (3.3)
White 32,418 (84.8) 10,068 (87.1) 5880 (88.0) 2601 (87.4)
Other 441 (1.2) 109 (0.9) 49 (0.7) 22 (0.7)
Education (%) < 0.0001
< High school, High school 10,498 (27.6) 3,426 (29.8) 1,936 (29.1) 893 (30.2)
Some college 9,905 (26.0) 3,009 (26.2) 1,808 (27.2) 838 (28.3)
College graduate, > College 17,656 (46.4) 5,069 (44.1) 2,899 (43.6) 1,228 (41.5)
Income in dollars (%) < 0.0001
< 35,000 12,759 (35.8) 3,631 (33.5) 1,902 (30.2) 925 (32.9)
35,000< 75,000 14,852 (41.7) 4,643 (42.9) 2,772 (44.0) 1,193 (42.4)
75,000 8,009 (22.5) 2,551 (23.6) 1,628 (25.8) 693 (24.7)
BMI (%) < 0.0001
<25kg/m
2
17,692 (46.5) 3,882 (33.7) 1,986 (29.9) 686 (23.2)
2530 kg/m
2
12,765 (33.6) 4,327 (37.6) 2,424 (36.5) 1,028 (34.7)
>30kg/m
2
7,572 (19.9) 3,301 (28.7) 2,234 (33.6) 1,245 (42.1)
Smokers (%) 1716 (4.5) 394 (3.4) 303 (4.5) 227 (7.7) < 0.0001
Alcohol intake (%) 0.086
< 0.5 drinks/week 22,086 (57.7) 6,812 (58.9) 3,875 (57.9) 1,769 (59.3)
0.52 drinks/week 5,821 (15.2) 1,684 (14.6) 1,001 (15.0) 467 (15.7)
> 2 drinks/week 10,352 (27.1) 3,077 (26.6) 1,812 (27.1) 745 (25.0)
HT users (%) < 0.0001
Never 12,548 (32.8) 3369 (29.1) 1896 (28.3) 878 (29.6)
Estrogen only 11,014 (28.8) 3623 (31.3) 2072 (31.0) 943 (31.7)
Either one or both 14,565 (38.1) 4541 (39.3) 2697 (40.3) 1136 (38.2)
Unknown 129 (0.3) 33 (0.3) 29 (0.4) 14 (0.5)
Physical activity (total energy expended, MET-hours/week, Mean ± SD) 12.0±13.4 12.1±13.4 11.6±13.0 11.9±13.2 0.38
Calibrated energy intake (kcal, Mean ± SD) 2033±187 2092±196 2130±209 2190±232 < 0.0001
Salt intake (mg, Mean ± SD) 2393±1077 2519±1098 2601±1193 2732±1388 < 0.0001
History of diabetes (%) 2636 (6.9) 1178 (10.2) 810 (12.1) 502 (16.8) < 0.0001
History of hypertension (%) 9962 (26.2) 3281 (28.5) 1956 (29.4) 927 (31.2) < 0.0001
History of high cholesterol (%) 4264 (11.4) 1512 (13.3) 844 (12.8) 384 (13.1) < 0.0001
Sugar-sweetened beverage intake 0.44
None or < 1/month 23,794 (62.1) 7,111 (61.4) 4,133 (61.7) 1,831 (61.3)
< Once a day 12,798 (33.4) 3,944 (34.0) 2,253 (33.6) 1,012 (33.9)
Daily 1,745 (4.6) 535 (4.6) 316 (4.7) 142 (4.8)
SD standard deviation, BMI body mass index, HT hormone therapy
*Unadjusted p value
Table 2. Incidence of Primary and Secondary Outcomes Across Diet Drink Consumption Strata
Outcomes Diet drink consumption
03/month 14/week 57/week 2/day p value*
Total subjects 38,337 11,590 6,702 2,985
Cardiovascular events (%)
Combined 2,745 (7.2) 785 (6.8) 462 (6.9) 254 (8.5) 0.010
CHD 1,030 (2.7) 279 (2.4) 159 (2.4) 94 (3.1) 0.055
HF 349 (0.9) 95 (0.8) 53 (0.8) 37 (1.2) 0.13
MI 819 (2.1) 219 (1.9) 122 (1.8) 74 (2.5) 0.065
Coronary revascularization 1,039 (2.7) 325 (2.8) 204 (3.0) 111 (3.7) 0.008
Stroke 652 (1.7) 192 (1.7) 94 (1.4) 58 (1.9) 0.212
PAD 160 (0.4) 49 (0.4) 27 (0.4) 22 (0.7) 0.079
Cardiac death 642 (1.7) 163 (1.4) 90 (1.3) 47 (1.6) 0.076
Mortality (%)
All cause death 2,970 (7.7) 789 (6.8) 445 (6.6) 233 (7.8) 0.003
CHD coronary heart disease, HF heart failure, MI myocardial infarction, PAD peripheral arterial disease
*Unadjusted p values (χ
2
test)
Vyas et al.: Diet Drinks and Cardiovascular Events JGIM
hazard ratios for the primary outcome (HR for 2 diet drink/
daygroup:1.3;95%CI1.11.5). Addition of the HEI-2005
score in the model also did not lead to any notable change in the
association between diet drink consumption and CVD events
(HR for 2 diet drinks/day group: 1.3; 95 % CI 1.11.5).
A significant unadjusted and adjusted interaction was ob-
served between baseline BMI and diet drink consumption for
the primary outcome (p=0.003 for both) (Online appendix).
On adjusted analysis, consumption of 2 diet drinks/day
continued to be significantly associated with occurrence of
CVD events in women with BMI 30 (HR 1.3, 95 % CI 1.1
1.6) and BMI < 25 (HR 1.7, 95 % CI 1.32.4), while the
association was not statistically significant in women with
BMI 2530 (HR 1.2, 95 % CI 0.91.5).
Finally, exclusion of HF from the primary outcome did not
change the hazard ratios significantly compared to the primary
analysis, and these continued to be statistically significant for
the 2 diet drinks/day group (Online appendix).
DISCUSSION
This study demonstrates an association between regular daily
intake of two or more diet drinks and CVD outcomes and
mortality in post-menopausal women. In our analysis, women
who consumed 2 diet drinks/day had a 30 % higher adjusted
risk of CVD events as well as overall mortality compared to
those with an intake of 03 diet drinks/month.
Our study, with nearly 60,000 subjects, is one of the largest
studies evaluating diet drink consumption and outcomes. Our
findings are concordant with the results of the only previous
report that expressly evaluated the risk of CVD events with diet
drink intake.
25
Gardener et al. used the Northern Manhattan
Study (NOMAS) cohort, and included 2,564 subjects (64 %
female). They found daily diet drink consumption to be asso-
ciated with an increased adjusted risk of CVD events (incident
stroke, MI or vascular death). The overall event rate was about
23 % over a mean follow-up of 9.8 years, which is significantly
higher than the total event rate of 7.1 % over 8.7 years in our
study; some of this may be explained by the presence of both
men and women in the NOMAS subject population, as well as
more ethnic diversity compared to the WHI cohort.
The results are also supported by other observational data
that have shown a link between diet drink consumption and
metabolic syndrome. Three separate reports, involving pa-
tients from the Framingham Heart Study, the Atherosclero-
sis Risk in Communities study and the Multi-Ethnic Study
of Atherosclerosis demonstrated significantly increased
rates of incident metabolic syndrome among subjects who
were frequent consumers of diet drinks.
2,8,9
Another report
that analyzed data from the San Antonio Heart Study noted a
greater incidence of obesity and a significantly higher
Table 3. Hazard Ratios for Primary and Secondary Outcomes
Across Diet Drink Consumption Strata
Models Outcomes
Cardiovascular events Cardiac death Overall death
HR (95 % CI) HR (95 % CI) HR (95 % CI)
Model I* N: 59,614 N: 59,447 N: 59,447
03/month 1.0 1.0 1.0
14/week 0.9 (0.91.02) 0.8 (0.70.99) 0.9 (0.80.9)
57/week 1.0 (0.91.1) 0.8 (0.60.99) 0.8 (0.80.9)
2/day 1.2 (1.041.3) 0.9 (0.71.2) 1.0 (0.91.1)
Model II
N: 55,073 N: 55,073 N: 55,073
03/month 1.0 1.0 1.0
14/week 1.0 (0.961.1) 1.0 (0.81.2) 1.0 (0.91.1)
57/week 1.1 (1.01.3) 1.1 (0.91.4) 1.1 (1.01.2)
2/day 1.6 (1.41.9) 1.8 (1.32.4) 1.5 (1.31.7)
Model III
N: 53,037 N: 53,037 N: 53,037
03/month 1.0 1.0 1.0
14/week 1.0 (0.91.1) 0.9 (0.81.1) 1.0 (0.91.1)
57/week 1.0 (0.91.1) 1.0 (0.81.3) 1.1 (1.01.2)
2/day 1.3 (1.21.5) 1.4 (1.041.9) 1.4 (1.21.6)
Model IV
§
N: 33,619
N: 33,619
N: 33,619
03/month 1.0 1.0 1.0
14/week 1.0 (0.91.1) 0.9 (0.71.2) 1.0 (0.91.1)
57/week 1.1 (0.91.2) 0.9 (0.71.3) 1.1 (0.91.2)
2/day 1.3 (1.11.5) 1.5 (1.032.3) 1.3 (1.041.5)
HR hazard ratios, CI confidence intervals
*Model I was unadjusted
Model II was adjusted for age, race, education and income
Model III was adjusted for the variables in Model II plus smoking
status, BMI, and a history of diabetes, hypertension and hyperlipidemia
§
Model IV was adjusted for the variables in Model III plus alcohol
intake, log calibrated energy intake, physical activity, sugar-sweetened
beverage intake, salt intake, and hormone therapy. Adjusted cardiac
event models were stratified on hypertension, and high cholesterol and
adjusted mortality models were stratified on hypertension and the
history of diabetes because these variables did not meet the proportional
hazards assumption
The majority of loss of patients in model 4 was secondary to missing
data for salt intake and calibrated energy
Table 4. Adjusted Hazard Ratios for Primary Outcome Across Diet
Drink Consumption Strata for Primary Analysis, for Baseline
Healthy Women, with Salt Intake and Calibrated Energy Intake
Excluded, and with Healthy Eating Index-2005 Included
Diet drink consumption
03/
month
14/
week
57/
week
2/day
HR
(95 % CI)
HR
(95 % CI)
HR
(95 % CI)
HR
(95 % CI)
Primary analysis*
N: 33,619 1.0
1.0 (0.91.1)1.1 (0.91.2)1.3 (1.11.5)
Baseline healthy
women
N: 22,417
1.0
1.0 (0.91.2)1.0 (0.81.2)1.2 (0.91.7)
Salt and calibrated
energy intake
excluded
N: 47,858
1.0
1.0 (0.91.1)1.0 (0.91.1)1.3 (1.11.5)
Healthy eating
index-2005 included
§
N: 44,869
1.0
1.0 (0.91.1)1.0 (0.91.2)1.3 (1.11.5)
HR hazard ratio, CI confidence interval
*Model IV: Adjusted for age, race, education, income, smoking status,
BMI, diabetes, hypertension, hyperlipidemia, alcohol intake, log
calibrated energy intake, physical activity, sugar-sweetened beverage
intake, salt intake, and hormone therapy
Model IV; Included women without a history of diabetes, hypertension,
and high cholesterol
Adjusted for Model IV excluding salt intake and calibrated energy
intake
§
Adjusted for Model IV including Healthy Eating Index-2005 scores and
excluding salt intake and calibrated energy intake
Vyas et al.: Diet Drinks and Cardiovascular EventsJGIM
increase in BMI with increasing intake of artificially sweet-
ened beverages, with an apparent dose response relationship
between the amount of artificially sweetened beverages
consumed and weight gain.
7
As both metabolic syndrome
and obesity are important risk factors for CVD, this may
contribute in part to the higher incidence of CVD events in
this population.
Exact pathophysiologic mechanisms that would explain the
association of weight gain, development of metabolic syn-
drome, and increased CVD events with diet soda consumption
are still unclear. One hypothesis is that artificial sweeteners
may increase the desire for sugar-sweetened, energy-dense
beverages/foods. Experimental data from animal (rat) models
suggests that consumption of products containing artificial
sweeteners may disrupt the correlation between sweet taste
and the energy content of foods (thus interfering with funda-
mental homeostatic and physiological processes).
26
Another
study investigating the functional magnetic resonance imaging
response to sucrose (a nutritive sweetener) and saccharin (a
nonnutritive sweetener) in diet soda drinkers versus non-diet
soda drinkers found alterations in the reward processing of
sweet taste in individuals who regularly consume diet soda.
27
An alternative explanation for this association could be
confounding by dietary patterns or incomplete adjustment
for confounders. In a recent study, diet beverage consumers
defined as having a healthy diet had a lower risk of metabolic
syndrome.
28
Analysis from the Health Professionals Follow-
Up Study presented evidence of an association between con-
sumption of sugar-sweetened beverages and increased CHD
risk and intermediate biomarkers, but no associations were
found for artificially sweetened beverage intake.
29
However,
the study noted that artificially sweetened beverage consump-
tion was associated with healthy lifestyle traits and higher
overall diet quality, which may suggest a role of dietary pattern
in the determination of outcomes. In addition, individuals
attempting to restrict energy intake and control weight may
be more likely to consider artificially sweetened beverages, a
factor that may influence CVD risk factor associations.
30
The
sensitivity analysis evaluating women without diabetes, hy-
pertension and high cholesterol at baseline was done to ad-
dress some of these questions. While the confidence intervals
widened (with loss of statistical significance), the hazard ratios
did not change significantly. Additionally, inclusion of the
HEI-2005 score, which is a validated tool for quantifying
dietary quality, also did not result in a significant change in
the association between diet drink consumption and CVD
events. Finally, the interaction between BMI and diet drink
intake noted in our analysis is an interesting finding that bears
further investigation, especially given other recent data that
highlight the role of body weight in this setting.
31
Limitations of this study include its observational nature,
and the fact that it involved retrospective analysis of data not
collected expressly for the purpose of this paper. It also in-
volves a specific population, that of post-menopausal women,
and thus may not be generalizable to other populations. As the
differences in demographic characteristics between women
excluded for missing diet drink data and the included women
demonstrate, presence of selection bias cannot be ruled out.
Due to limited data collection regarding diet drink intake after
the baseline evaluation, the analysis does not take into account
changes in consumption pattern over the course of follow-up.
Finally, the association seen in this study does not translate
into causality, and may be due to confounding variables that
were not examined in multivariate analysis, or may not even
be clearly defined as being confounders in this relationship as
of yet.
In conclusion, this study suggests an association between
consumption of two or more diet drinks per day and adverse
CVD events, as well as increased mortality. However, further
evaluation with other clinical studies, animal models and even
molecular and pharmacologic analyses is needed to confirm or
disprove this link, and to assess a possible causal relationship
between diet drink intake and increased CVD risk.
Funding Sources: The Division of Cardiovascular Medicine at the
University of Iowa Hospitals & Clinics and the Womens Health Initia-
tive provided partial funding for this manuscript.
Conflict of Interest: The authors declare that they do not have a
conflict of interest.
Relationship with Industry: None.
Corresponding Author: Ankur Vyas, MD; Division of Cardiovascular
MedicineUniversity of Iowa Hospitals Clinics, 200 Hawkins Dr., Int. Med.
E316-1 GH, Iowa City, IA 52242, USA (e-mail: ankurvyas7@gmail.com).
REFERENCES
1. Fung TT, Malik V, Rexrode KM, Manson JE, Willett WC, Hu FB. Sweetened
beverage consumption and risk of coronary heart disease in women. Am J
Clin Nutr. 2009;89(4):10371042. doi:10.3945/a jcn.2008. 27140.
2. Dhingra R, Sullivan L, Jacques PF, et al. Soft drink consumption and
risk of developing cardiometabolic risk factors and the metabolic syndrome
in middle-aged adults in the community. Circulation. 2007;116(5):480
488. doi:10.1161/CIRCULATIONAHA.107.689935.
3. Malik VS, Popkin BM, Bray GA, Després J-P, Hu FB. Sugar-sweetened
beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease
risk. Circulation. 2010;121(11):13561364. doi:10.1161/
CIRCULATIONAHA.109.876185.
4. Qi Q, Chu AY, Kang JH, et al. Sugar-sweetened beverages and genetic risk
of obesity. N Engl J Med. 2012;367(15):13871396. doi:10.1056/
NEJMoa1203039.
5. Schulze MB, Manson JE, Ludwig DS, et al. Sugar-sweetened beverages,
weight gain, and incidence of type 2 diabetes in young and middle-aged
women. JAMA. 2004;292(8):927934. doi:10.1001/jama.292.8.927.
6. Fakhouri THI, Kit BK, Ogden CL. Consumption of diet drinks in the
United States, 20092010. NCHS Data Brief. 2012;109:18.
7. Fowler SP, Williams K, Resendez RG, Hunt KJ, Hazuda HP, Stern MP. Fueling
the obesity epidemic? Artificially sweetened beverage use and long-term
weight gain. Obesity. 2008;16(8):18941900. doi:10.1038/oby.2008.284.
8. Nettleton JA, Lutsey PL, Wang Y, Lima JA, Michos ED, Jacobs DR. Diet
soda intake and risk of incident metabolic syndrome and type 2 diabetes in
the Multi-E thnic Study of Atherosclerosis (MESA). Diabetes Care.
2009;32(4):688694. doi:10.2337/dc08-1799.
9. Lutsey PL, Steffen LM, Stevens J. Dietary intake and the development of the
metabolic syndrome: the atherosclerosis risk in communities study. Circulation.
2008;117(6):754761. doi:10.1161/CIRCULATIONAHA.107.716159.
Vyas et al.: Diet Drinks and Cardiovascular Events JGIM
10. Rossouw JE, Hurd S. The Womens Health Initiative: recruitment
completelooking back and looking forward. J Womens Health.
1999;8(1):35.
11. Hays J, Hunt JR, Hubbell FA, et al. The Womens Health Initiative
recruitment methods and results. Ann Epidemiol. 2003;13(9 Suppl):S18
77. doi:10.1016/S1047-2797(03)00042-5.
12. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M.
The Womens Health Initiative Observational Study: baseline charac-
teristics of participants and reliability of baseline measures. Ann
Epidemiol. 2003;13(9 Suppl):S10721. doi:10.1016/S1047-
2797(03)00047-4.
13. The Womens Health Initiative Study Group. Design of the Womens Health
Initiative clinical trial and observational study. Control Clin Trials.
1998;19(1):61109.
14. Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-
Collins T. Measurement characteristics of the Womens Health Initiative
food frequency questionnaire. Ann Epidemiol. 1999;9(3):178187.
15. Curb JD, Mctiernan A, Heckbert SR, et al. Outcomes ascertainment and
adjudication methods in the Womens Health Initiative. Ann Epidemiol.
2003;13(9 Suppl):S1228. doi:10.1016/S1047-2797(03)00048-6.
16. Margolis KL,Lihong Q, Brzyski R, etal. Validity of diabetes self-reports in
the Womens Health Initiative: comparison with medication inventories and
fasting glucose measurements. Clin Trials. 2008;5(3):240247.
doi:10.1177/1740774508091749.
17. Neuhouser ML,Tinker L, Shaw PA, et al. Use of recovery biomarkers t o
calibrate nutrient consumption self-reports in the WomensHealth
Initiative. Am J Epidemiol. 2008;167(10):12471259. doi:10.1093/
aje/kwn026.
18. Cox DR. Regression models and life-tables. J R S tat Soc Ser B.
1972;34:187220.
19. Nicklas TA, ONeil CE, Fulgoni VL. Diet quality is inversely related to
cardiovascular risk factors in adults. J Nutr. 2012;142(12):21122118.
doi:10.3945/jn.112.164889.
20. Chiuve SE, Fung TT, Rimm EB, et al. Alternative dietary indices both
strongly predict risk of chronic disease. J Nutr. 2012;142(6):10091018.
doi:10.3945/jn.111.157222.
21. George SM, Ballard-Barbash R, Shikany JM, et al. Better postdiagnosis
diet quality is associated with reduced risk of death among postmeno-
pausal women with invasive breast cancer in the Womens Health Initiative.
Cancer Epidemiol Biomark Prev. 2014;23(4):575583. doi:10.1158/1055-
9965.EPI-13-1162.
22. Guenther PM, Reedy J, Krebs-Smith SM. Development of the healthy
eating index-2005. J Am Diet Assoc. 2008;108(11):18961901.
doi:10.1016/j.jada.2008.08.016.
23. Guenther PM, Reedy J, Krebs-Smith SM, Reeve BB. Evaluation of the
healthy eating index-2005. J Am Diet A ssoc. 2008;108(11):18541864.
doi:10.1016/j.jada.2008.08.011.
24. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC,
Van d en br o uck e J P. The Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement: guidelines for reporting
observational studies. Ann Intern Med. 2007;147(8):573577.
doi:10.7326/0003-4819-147-8-200710160-00010.
25. Gardener H, Rundek T, Markert M, Wright CB, Elkind MSV, Sacco RL.
Diet soft drink consumption is associated with an increased risk of
vascular events in the Northern Manhattan Study. J Gen Intern Med.
2012;27(9):11201126. d oi: 10.1007/s11606-011-1968-2.
26. Swithers SE, Davidson TL. A role for sweet taste: calorie predictive
relations in energy regulation by rats. Behav Neurosci. 2008;122(1):161
173. doi:10.1037/0735-7044.122.1.161.
27. Green E, Murphy C. Altered processing of sweet taste in the brain of diet
soda drinkers. Physiol Behav. 2012;107(4):560567. doi:10.1016/
j.physbeh.2012.05.006.
28. Duffey KJ, Steffen LM, Van Horn L, Jacobs DR, Popkin BM. Dietary
patterns matter: diet beverages and cardiometabolic risks in the
longitudinal Coronary Artery Risk Development in Young Adults
(CARDIA) Study. Am J Clin Nutr. 2012;95(4):909915. doi:10.3945/
ajcn.111.026682.
29. de Koning L, Malik VS, Kellogg MD, Rimm EB, Willett WC, Hu FB.
Sweetened beverage consumption, incident coronary heart disease, and
biomarkers of risk in men. Circula tion. 2012;125(14):17 3541-S1.
doi:10.1161/CIRCULATIONAHA.111.067017.
30. Elfhag K, Tynelius P, Rasmussen F. Sugar-sweetened and artificially
sweetened soft drinks in association to restrained, external and emotional
eating. Physiol Behav. 2007;91(23):191195. doi:10.1016/
j.physbeh.2007.02.005.
31. Bleich SN, Wolfson JA, Vine S, Wang YC. Diet-beverage consumption and
caloric intake among US adults, overall and by body weight. Am J Public
Health. 2014:e1e7. doi:10.2105/AJPH.2013.301556.
Vyas et al.: Diet Drinks and Cardiovascular EventsJGIM
... However, prospective cohort studies have demonstrated higher ASB intakes in relation to higher risks of cardiometabolic diseases, such as obesity, type 2 diabetes, and cardiovascular disease (CVD) [8][9][10]. Furthermore, several cohort studies have reported harmful or null associations of ASB intake with mortality among the general population [11][12][13][14][15][16][17]. These associations have been meta-analyzed, and unfavorable pooled associations were observed between ASB intake with all-cause and CVD mortality among a total of approximately 940,000 participants [18][19][20]. ...
... Of the 11 studies, seven were conducted in the US [11, 13-15, 17, 22, 23] and four in Europe [12,16,21,24]. Two studies focused exclusively on women [14,15], and nine on men and women together [11-13, 16, 17, 21-24]. Eight studies measured dietary data using food questionnaires [11-15, 17, 23, 24], while the other three applied 24-h dietary recalls [16,21,22]. ...
... For the current study, ten studies were included in the highest vs. lowest ASB intake meta-analysis [11][12][13][14][15][16][21][22][23][24], ten in per-serving/day of ASB meta-analysis [11,12,[15][16][17][18][21][22][23][24], and nine in the dose-response meta-analysis [11-13, 15, 16, 21, 22, 24]. ...
Article
Full-text available
Background Artificially sweetened beverages (ASB) are consumed globally, but their impact on overall health remains uncertain. We summarized published associations between ASB intake with all-cause and cause-specific mortality. Methods We searched Medline, Embase, Web of Science, and Cochrane CENTRAL databases until August 2023. Random effect meta-analysis was conducted to calculate pooled risk ratios (RRs) and 95% confidence intervals (95%CIs) for highest versus lowest categories of ASB consumption in relation to all-cause and cause-specific mortality. Linear and non-linear dose-response analyses were also performed. Results Our systematic review and meta-analysis included 11 prospective cohort studies. During a median/mean follow-up period of 7.0 to 28.9 years, 235,609 deaths occurred among 2,196,503 participants. Intake of ASB was associated with higher risk of all-cause and CVD mortality with pooled RRs (95%CIs) of highest vs. lowest intake categories of 1.13 (1.06, 1.21) (I² = 66.3%) for all-cause mortality and 1.26 (1.10, 1.44) (I² = 52.0%) for CVD mortality. Dose-response analysis revealed a non-linear association of ASB with all-cause mortality (pnon−linearity = 0.01), but a linear positive association with CVD mortality (pnon−linearity = 0.54). No significant association was observed for ASB intake and cancer mortality. Moreover, a secondary meta-analysis demonstrated that replacing 1 serving/day of sugary sweetened beverages (SSB) with ASB was associated with 4–6% lower risk of all-cause and CVD mortality. Per NutriGrade, the evidence quality for associations between ASB intake with all-cause and CVD mortality was moderate. Conclusions Higher intake of ASB was associated with higher risk of all-cause and CVD mortality, albeit a lower risk than for SSB. Systematic review registration PROSPERO registration no. CRD42022365701.
... Thus, artificial sweeteners, as an additive that can reproduce sweetness without the use of sugar, have been widely replacing added sugar in recent years [6,7]. Nevertheless, some previous studies have reported potential relationships between artificial sweeteners and CVD risk, with mixed evidence [8][9][10][11][12][13][14][15][16][17][18][19][20][21]. It should be noted that those observational perspective studies have mostly used low-calorie beverages or artificial sweetened beverages (ASB) as proxies to explore their effects on CVD risk, without considering the confounding effects of other substances in beverages and tabletop artificial sweeteners (e.g., Canderel) added to the daily diet, which is also a major source of artificial sweetener intake and has simpler ingredients. ...
... The CVD risk associated with artificial sweeteners is independent of genetic susceptibility, and no significant interaction exists between genetic susceptibility and artificial sweeteners. For the constructed CAD, PAD, and HF PRS, we observed that participants with high genetic risk according to PRS had a higher risk of incident CAD (Table S12- 14). Associations between artificial sweetener intake and overall CVD, CAD, PAD, and HF incidence stratified by low and high PRS are presented in Table 4. ...
... In specific CVD subtypes (CAD, PAD, and HF), the proportion of IE ranges from 68.2 to 79.9%. While some studies of ASB and CVD have implied possible associations between artificial sweeteners and CVD [14,15,18,19], there is only one other large-scale prospective study from the NutriNet-Sante cohort that has specifically examined the association between artificial sweetener intake and CVD [21]. In line with the results from the NutriNet-Sante cohort, our study, based on large-scale population data from the UK Biobank, confirms the significant association between artificial sweeteners rather than ASB and overall CVD. ...
... Thus, artificial sweeteners, as an additive that can reproduce sweetness without the use of sugar, have been widely replacing added sugar in recent years [6,7]. Nevertheless, some previous studies have reported potential relationships between artificial sweeteners and CVD risk, with mixed evidence [8][9][10][11][12][13][14][15][16][17][18][19][20][21]. It should be noted that those observational perspective studies have mostly used low-calorie beverages or artificial sweetened beverages (ASB) as proxies to explore their effects on CVD risk, without considering the confounding effects of other substances in beverages and tabletop artificial sweeteners (e.g., Canderel) added to the daily diet, which is also a major source of artificial sweetener intake and has simpler ingredients. ...
... The CVD risk associated with artificial sweeteners is independent of genetic susceptibility, and no significant interaction exists between genetic susceptibility and artificial sweeteners. For the constructed CAD, PAD, and HF PRS, we observed that participants with high genetic risk according to PRS had a higher risk of incident CAD (Table S12- 14). Associations between artificial sweetener intake and overall CVD, CAD, PAD, and HF incidence stratified by low and high PRS are presented in Table 4 And the multiplicative interaction analyses also did not disclose any significant interactions (Table 4). ...
... In specific CVD subtypes (CAD, PAD, and HF), the proportion of IE ranges from 68.2 to 79.9%. While some studies of ASB and CVD have implied possible associations between artificial sweeteners and CVD [14,15,18,19], there is only one other large-scale prospective study from the NutriNet-Sante cohort that has specifically examined the association between artificial sweetener intake and CVD [21]. In line with the results from the NutriNet-Sante cohort, our study, based on large-scale population data from the UK Biobank, confirms the significant association between artificial sweeteners rather than ASB and overall CVD. ...
Article
Full-text available
Background Artificial sweeteners are widely popular worldwide as substitutes for sugar or caloric sweeteners, but there are still several important unknowns and controversies regarding their associations with cardiovascular disease (CVD). We aimed to extensively assess the association and subgroup variability between artificial sweeteners and CVD and CVD mortality in the UK Biobank cohort, and further investigate the modification effects of genetic susceptibility and the mediation role of type 2 diabetes mellitus (T2DM). Methods This study included 133,285 participants in the UK Biobank who were free of CVD and diabetes at recruitment. Artificial sweetener intake was obtained from repeated 24-hour diet recalls. Cox proportional hazard models were used to estimate HRs. Genetic predisposition was estimated using the polygenic risk score (PRS). Furthermore, time-dependent mediation was performed. Results In our study, artificial sweetener intake (each teaspoon increase) was significantly associated with an increased risk of incident overall CVD (HR1.012, 95%CI: 1.008,1.017), coronary artery disease (CAD) (HR: 1.018, 95%CI: 1.001,1.035), peripheral arterial disease (PAD) (HR: 1.035, 95%CI: 1.010,1.061), and marginally significantly associated with heart failure (HF) risk (HR: 1.018, 95%CI: 0.999,1.038). In stratified analyses, non-whites were at greater risk of incident overall CVD from artificial sweetener. People with no obesity (BMI < 30 kg/m²) also tended to be at greater risk of incident CVD from artificial sweetener, although the obesity interaction is not significant. Meanwhile, the CVD risk associated with artificial sweeteners is independent of genetic susceptibility, and no significant interaction exists between genetic susceptibility and artificial sweeteners in terms of either additive or multiplicative effects. Furthermore, our study revealed that the relationship between artificial sweetener intake and overall CVD is significantly mediated, in large part, by prior T2DM (proportion of indirect effect: 70.0%). In specific CVD subtypes (CAD, PAD, and HF), the proportion of indirect effects ranges from 68.2 to 79.9%. Conclusions Our findings suggest significant or marginally significant associations between artificial sweeteners and CVD and its subtypes (CAD, PAD, and HF). The associations are independent of genetic predisposition and are mediated primarily by T2DM. Therefore, the large-scale application of artificial sweeteners should be prudent, and the responses of individuals with different characteristics to artificial sweeteners should be better characterized to guide consumers’ artificial sweeteners consumption behavior.
... The consumption of ASBs worldwide has gradually increased in recent years (Fakhouri et al., 2012;Sylvetsky et al., 2012;Moriconi et al., 2020). However, accumulating studies in the last decade suggested that ASB consumption might be associated with an increased risk of cardiovascular events and diabetes (Fung et al., 2009;de Koning et al., 2012;Fagherazzi et al., 2013;Gardener et al., 2012;Drouin-Chartier et al., 2019;de Koning et al., 2011;Hirahatake et al., 2019;Mossavar-Rahmani et al., 2019;Vyas et al., 2015). Nevertheless, the underlying mechanisms responsible for these findings remain insufficiently documented. ...
... Taken together, our results suggested that both caloric and noncaloric monosaccharides treatment could lead to excessive angiogenesis by promoting the differentiation of quiescent ECs into tip cells through the foxo1a-marcksl1a pathway. Previous studies have linked the consumption of ASB to the occurrence and development of cardiovascular disease (Fung et al., 2009;de Koning et al., 2012;Fagherazzi et al., 2013;Gardener Drouin-Chartier et al., 2019;de Koning et al., 2011;Hirahatake et al., 2019;Mossavar-Rahmani et al., 2019;Vyas et al., 2015). However, the potential mechanisms underlying the association have not been well documented. ...
Article
Full-text available
Artificially sweetened beverages containing noncaloric monosaccharides were suggested as healthier alternatives to sugar-sweetened beverages. Nevertheless, the potential detrimental effects of these noncaloric monosaccharides on blood vessel function remain inadequately understood. We have established a zebrafish model that exhibits significant excessive angiogenesis induced by high glucose, resembling the hyperangiogenic characteristics observed in proliferative diabetic retinopathy (PDR). Utilizing this model, we observed that glucose and noncaloric monosaccharides could induce excessive formation of blood vessels, especially intersegmental vessels (ISVs). The excessively branched vessels were observed to be formed by ectopic activation of quiescent endothelial cells (ECs) into tip cells. Single-cell transcriptomic sequencing analysis of the ECs in the embryos exposed to high glucose revealed an augmented ratio of capillary ECs, proliferating ECs, and a series of upregulated proangiogenic genes. Further analysis and experiments validated that reduced foxo1a mediated the excessive angiogenesis induced by monosaccharides via upregulating the expression of marcksl1a . This study has provided new evidence showing the negative effects of noncaloric monosaccharides on the vascular system and the underlying mechanisms.
... 29 One primary cohort study considered composite CVD outcomes; therefore, we could not include this study in the meta-analyses on either stroke or CHD. 30 We excluded 5 primary cohort studies for meta-analysis on T2D because of the following reasons: were conducted on women with gestational diabetes mellitus (GDM) 31 ; considered only 1 MetS component, high fasting glucose levels as T2D incidence 32 ; considered prediabetes as the outcome of interest instead of T2D 33 ; and were duplicate studies within the same population with a shorter follow-up period. 34,35 In addition, 3 primary studies provided data for 1 of the components of MetS (high blood pressure) as HTN incidence and were included in the published meta-analyses 32,36,37 ; therefore, these 3 studies were excluded from our metaanalysis. ...
Article
Context Several effects of non–sugar-sweetened beverage (NSSBs) intake on health outcomes have been reported; however, the evidence on the association between NSSBs intake and chronic diseases and mortality risk is still inconclusive. Objective This umbrella review aimed to summarize the evidence on the association between NSSBs intake and the risk of chronic diseases and mortality. Data Sources Embase, ISI Web of Science, Cochrane Central, and PubMed were searched up to September 2023 for relevant meta-analyses of observational prospective cohort studies. Data Extraction Two groups of researchers independently extracted study data and assessed the risk of bias for meta-analyses and primary studies. Data Analysis Six meta-analyses, reporting 74 summary hazard ratios (HRs) for different outcomes obtained from 50 primary studies, were included. The summary HRs, 95% CIs, and certainty of evidence on the association of NSSBs intake with risk of chronic diseases and mortality were as follows: all-cause mortality (per 355 mL/d: 1.06 [1.01 to 1.10]; moderate certainty); stroke (per 250 mL/d: 1.09 [1.04 to 1.13]; high certainty); coronary heart disease (CHD) (per 250 mL/d: 1.06 [1.02 to 1.11]; high certainty); hypertension (HTN) (high vs low intake: 1.14 [1.09 to 1.18]; moderate certainty); type 2 diabetes (T2D) (high vs low intake: 1.16 [1.08 to 1.26]; low certainty); metabolic syndrome (MetS) (high vs low intake: 1.32 [1.22 to 1.43]; low certainty); colorectal cancer (high vs low intake: 0.78 [0.62 to 0.99]; moderate certainty); and leukemia (high vs low intake: 1.35 [1.03 to 1.77]; moderate certainty). For other outcomes, including the risk of cardiovascular and cancer mortality, chronic kidney diseases, breast cancer, prostate cancer, endometrial cancer, pancreatic cancer, multiple myeloma, and non-Hodgkin lymphoma, no association was found. Conclusion This study provides further evidence that NSSBs are associated with increased risk of all-cause mortality, stroke, CHD, HTN, T2D, MetS, and leukemia. Moreover, a higher intake of NSSBs was associated with a lower risk of colorectal cancer. However, it should be noted that the magnitudes of the associations are not large. Further studies are needed to clarify the long-term effects of different NSSBs intakes on health. Systematic Review Registration PROSPERO no. CRD42023429981.
... Several cohorts have found links between artificially sweetened beverages and CVD, which is consistent with this latest research. In the Women's Health Initiative, higher intake of artificially sweetened beverages was associated with increased risks of ischemic stroke and coronary artery disease (Mossavar-Rahmani et al., 2019;Vyas et al., 2014). Consuming NNS is linked to higher risks of being overweight, having hypertension, a condition known as metabolic syndrome, type 2 diabetes, stroke, and CVD events, according to certain research. ...
Article
Full-text available
There is a recent trend showing an uptick in the artificial sweetener's usage, particularly the nonnourishing variety. The allure of a low‐calorie choice that lets people indulge in their sweet tooths while consuming less calories overall is what motivates this. Children's food products often contain a substantial number of artificial sweeteners due to their properties that aid in moisture retention, act as fillers, and serve as bulking agents. This article provides a comprehensive overview of artificial sweeteners and influences in human wealth. Studies have linked the use of artificial sweeteners to premature birth, highlighting the teratogenic potential of these compounds, particularly in beverages. Pregnant women who incorporate nonnutritive sweeteners into their diet during pregnancy are more likely to have children with birth defects, as indicated by studies on the subject. Artificial sweeteners should not be added to food for children because studies show that eating them while a child's body is still developing might disturb the balance of gut microbiota and cause potential problems like heart disease, stroke, and cognitive decline. The ingestion of nonnourishing sweeteners has adverse effects on the fertility of both men and women. Studies indicate that exceeding the recommended daily consumption that the FDA has set for artificial sweeteners can result in conditions of infertility for both genders. Additionally, there is a connection between the onset of cancer and the use of artificial sweeteners. Presently, a considerable amount of research relies on animal models rather than human ones, creating a notable gap in research. The limitation of extensive human model studies represents a drawback in validating results. Furthermore, there is a necessity for increased research focused on advancing techniques that can minimize the adverse effects of artificial sweeteners, making them more suitable for addressing issues related to obesity and various types of diabetes.
Article
Full-text available
Artificial sweeteners, prominently exemplified by sucralose, have become pervasive in contemporary diets, prompting intriguing questions about their impact on metabolism and their potential role in the unfolding trends of obesity. Covering topics from its discovery to analytical methods for detection and determination in food samples, the manuscript scrutinizes the metabolic effects of sucralose. Notably, the association between sucralose intake and obesity is examined, challenging the conventional belief of its role in weight management. The document comprehensively examines in vivo studies, revealing sucralose's implications on insulin resistance, gut microbiota, and metabolic syndrome, providing a nuanced comprehension of its impact on human health. Additionally, it explores sucralose's effects on glucose and lipid metabolism, blood pressure, and cardiovascular health, underscoring its possible involvement in malignancy development. The review concludes with a call for increased public awareness, education, and updated dietary guidelines to help individuals make informed choices about sweetener consumption. The future perspectives section highlights the need for longitudinal studies, exploring alternative sweeteners, and refining acceptable daily intake limits to ensure public health recommendations align with evolving regulatory guidelines. Overall, the manuscript provides a comprehensive overview of sucralose's multifaceted impact on health, urging further research and a balanced perspective on sweetener consumption.
Article
Full-text available
Purpose of Review Artificial sweeteners have become increasingly popular in today’s dietary trends as a healthier and sweeter alternative to sugar. As studies emerge regarding artificial sweeteners, concerns are arising about their side effects, particularly linking them to strokes. This systematic review aims to assess the relationship between artificial sweeteners (AS) and cerebrovascular accidents (CVAs). A systematic search of studies indexed in PubMed and Google Scholar was conducted using the keywords “ASB” (artificially sweetened beverage), “Artificial Sweeteners,” “Stroke,” etc. These studies were screened and filtered according to our exclusion criteria. We reviewed 55 studies published in various journals and further boiled down to finalizing 12 studies for analysis using the PRISMA Statement (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020. Recent Findings Most studies suggest that there is a positive association between artificial sweetener consumption and CVAs including all types of strokes, particularly ischemic strokes. Poorer outcomes are seen with higher ASB intake. Increased risk is notable among women and black populations. Some studies show no association between ASB consumption and hemorrhagic stroke, however, most suggest a strong link. Summary The current literature shows a degree of variation so it is crucial to consider possible confounders and eliminate them in future studies. Further research is necessary to determine the underlying mechanisms, especially in individuals with comorbidities. The results obtained play a role in forming dietary guidelines and alarming the public about the possible health implications, prompting caution regarding excessive consumption of artificial sweeteners, in their daily lives.
Preprint
Artificially sweetened beverages containing noncaloric monosaccharides were suggested as healthier alternatives to sugar-sweetened beverages. Nevertheless, the potential detrimental effects of these noncaloric monosaccharides on blood vessel function remain inadequately understood. Presently, we have established a zebrafish model that exhibits significant excessive angiogenesis induced by high glucose, resembling the hyperangiogenic characteristics observed in proliferative diabetic retinopathy (PDR). Utilizing this model, we observed that glucose and noncaloric monosaccharides could induce excessive formation of blood vessels, especially intersegmental vessels (ISVs). The excessively branched vessels were observed to be formed by ectopic activation of quiescent endothelial cells (ECs) into tip cells. Single-cell transcriptomic sequencing analysis of the endothelial cells in the embryos exposed to high glucose revealed an augmented ratio of capillary ECs, proliferating ECs, and a series of upregulated proangiogenic genes. Further analysis and experiments validated that foxo1a mediated the excessive angiogenesis induced by monosaccharides by down-regulating the expression of marcksl1a . This study has provided new evidence showing the negative effects of noncaloric monosaccharides on the vascular system and the underlying mechanisms.
Article
Full-text available
Background: Few studies have evaluated whether adherence to dietary recommendations is associated with mortality among cancer survivors. In breast cancer survivors, we examined how postdiagnosis Healthy Eating Index (HEI)-2005 scores were associated with all-cause and cause-specific mortality. Methods: Our prospective cohort study included 2,317 postmenopausal women, ages 50 to 79 years, in the Women's Health Initiative's Dietary Modification Trial (n = 1,205) and Observational Study (n = 1,112), who were diagnosed with invasive breast cancer and completed a food frequency questionnaire after being diagnosed. We followed women from this assessment forward. We used Cox proportional hazards models to estimate multivariate-adjusted HRs and 95% confidence intervals (CI) for death from any cause, breast cancer, and causes other than breast cancer, according to HEI-2005 quintiles. Results: Over 9.6 years, 415 deaths occurred. After adjustment for key covariates, women consuming better quality diets had a 26% lower risk of death from any cause (HRQ4:Q1, 0.74; 95% CI, 0.55-0.99; Ptrend = 0.043) and a 42% lower risk of death from non-breast cancer causes (HRQ4:Q1, 0.58; 95% CI, 0.38-0.87; Ptrend = 0.011). HEI-2005 score was not associated with breast cancer death (HRQ4:Q1, 0.91; 95% CI, 0.60-1.40; Ptrend = 0.627). In analyses stratified by tumor estrogen receptor (ER) status, better diet quality was associated with a reduced risk of all-cause mortality among women with ER(+) tumors (n = 1,758; HRQ4:Q1, 0.55; 95% CI, 0.38-0.79; Ptrend = 0.0009). Conclusion: Better postdiagnosis diet quality was associated with reduced risk of death, particularly from non-breast cancer causes. Impact: Breast cancer survivors may experience improved survival by adhering to U.S. dietary guidelines.
Article
... 8. Ludwig DS, Peterson KE, Gortmaker SL. Relation between consumption of sugar - sweetened drinks and childhood obesity : a prospective, observational analysis. Lancet. 2001;357:505-508.pmid:11229668. ...
Article
Much biomedical research is observational. The reporting of such research is often inadequate, which hampers the assessment of its strengths and weaknesses and of a study's generalizability. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Initiative developed recommendations on what should be included in an accurate and complete report of an observational study. We defined the scope of the recommendations to cover 3 main study designs: cohort, case-control, and cross-sectional studies. We convened a 2-day workshop in September 2004, with methodologists, researchers, and journal editors, to draft a checklist of items. This list was subsequently revised during several meetings of the coordinating group and in e-mail discussions with the larger group of STROBE contributors, taking into account empirical evidence and methodological considerations. The workshop and the subsequent iterative process of consultation and revision resulted in a checklist of 22 items (the STROBE Statement) that relate to the title, abstract, introduction, methods, results, and discussion sections of articles. Eighteen items are common to all 3 study designs and 4 are specific for cohort, case-control, or cross-sectional studies. A detailed Explanation and Elaboration document is published separately and is freely available at www.annals.org and on the Web sites of PLoS Medicine and Epidemiology. We hope that the STROBE Statement will contribute to improving the quality of reporting of observational studies.
Article
Background: Temporal increases in the consumption of sugar-sweetened beverages have paralleled the rise in obesity prevalence, but whether the intake of such beverages interacts with the genetic predisposition to adiposity is unknown. Methods: We analyzed the interaction between genetic predisposition and the intake of sugar-sweetened beverages in relation to body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) and obesity risk in 6934 women from the Nurses' Health Study (NHS) and in 4423 men from the Health Professionals Follow-up Study (HPFS) and also in a replication cohort of 21,740 women from the Women's Genome Health Study (WGHS). The genetic-predisposition score was calculated on the basis of 32 BMI-associated loci. The intake of sugar-sweetened beverages was examined prospectively in relation to BMI. Results: In the NHS and HPFS cohorts, the genetic association with BMI was stronger among participants with higher intake of sugar-sweetened beverages than among those with lower intake. In the combined cohorts, the increases in BMI per increment of 10 risk alleles were 1.00 for an intake of less than one serving per month, 1.12 for one to four servings per month, 1.38 for two to six servings per week, and 1.78 for one or more servings per day (P<0.001 for interaction). For the same categories of intake, the relative risks of incident obesity per increment of 10 risk alleles were 1.19 (95% confidence interval [CI], 0.90 to 1.59), 1.67 (95% CI, 1.28 to 2.16), 1.58 (95% CI, 1.01 to 2.47), and 5.06 (95% CI, 1.66 to 15.5) (P=0.02 for interaction). In the WGHS cohort, the increases in BMI per increment of 10 risk alleles were 1.39, 1.64, 1.90, and 2.53 across the four categories of intake (P=0.001 for interaction); the relative risks for incident obesity were 1.40 (95% CI, 1.19 to 1.64), 1.50 (95% CI, 1.16 to 1.93), 1.54 (95% CI, 1.21 to 1.94), and 3.16 (95% CI, 2.03 to 4.92), respectively (P=0.007 for interaction). Conclusions: The genetic association with adiposity appeared to be more pronounced with greater intake of sugar-sweetened beverages. (Funded by the National Institutes of Health and others.).
Article
Objectives: We examined national patterns in adult diet-beverage consumption and caloric intake by body-weight status. Methods: We analyzed 24-hour dietary recall with National Health and Nutrition Examination Survey 1999-2010 data (adults aged ≥ 20 years; n = 23 965). Results: Overall, 11% of healthy-weight, 19% of overweight, and 22% of obese adults drink diet beverages. Total caloric intake was higher among adults consuming sugar-sweetened beverages (SSBs) compared with diet beverages (2351 kcal/day vs 2203 kcal/day; P = .005). However, the difference was only significant for healthy-weight adults (2302 kcal/day vs 2095 kcal/day; P < .001). Among overweight and obese adults, calories from solid-food consumption were higher among adults consuming diet beverages compared with SSBs (overweight: 1965 kcal/day vs 1874 kcal/day; P = .03; obese: 2058 kcal/day vs 1897 kcal/day; P < .001). The net increase in daily solid-food consumption associated with diet-beverage consumption was 88 kilocalories for overweight and 194 kilocalories for obese adults. Conclusions: Overweight and obese adults drink more diet beverages than healthy-weight adults and consume significantly more solid-food calories and a comparable total calories than overweight and obese adults who drink SSBs. Heavier US adults who drink diet beverages will need to reduce solid-food calorie consumption to lose weight.
Article
Ein Großteil der biomedizinischen Forschung ist beobachtend, und die Qualität der veröffentlichten Berichte über diese Forschung ist oft unzureichend. Dies behindert die Beurteilung der Stärken und Schwächen einer Studie und ihrer Übertragbarkeit. Die Strengthening the Reporting of Observational Studies in Epidemiology (STROBE-) Initiative hat Empfehlungen entwickelt, was in einem akkuraten und vollständigen Bericht einer Beobachtungsstudie enthalten sein sollte. Die Empfehlungen wurden von uns so definiert, dass sie 3 Hauptstudientypen abdecken: Kohorten-, Fallkontroll- und Querschnittsstudien. Im September 2004 veranstalteten wir einen zweitägigen Workshop mit Methodikern, Forschern und Herausgebern wissenschaftlicher Zeitschriften, um eine Checkliste zu entwerfen. Anschließend wurde der Entwurf bei mehreren Treffen der Koordinierungsgruppe und nach E-Mail-Diskussionen mit der erweiterten STROBE-Gruppe revidiert und dabei empirische Evidenz und methodologische Aspekte berücksichtigt. Das Ergebnis des Workshops und des anschließenden iterativen Prozesses aus Beratung und Revision war eine Checkliste von 22 Punkten (STROBE-Statement), die sich auf die Bereiche Titel, Abstract, Einleitung, Methoden, Ergebnisse und Diskussion eines Artikels beziehen. 18 der Punkte sind relevant für alle 3 Studiendesigns, während 4 der Punkte spezifisch für Kohorten-, Fallkontroll- und Querschnittsstudien sind. Ein ausführlicher Begleitartikel (Explanation and Elaboration) wurde separat veröffentlicht und ist auf den Webseiten von PLoS Medicine, Annals of Internal Medicine und Epidemiology frei zugänglich. Wir hoffen, dass das STROBE-Statement dazu beitragen kann, dass Beobachtungsstudien besser berichtet werden.